Gastric cancer cell glycosylation as a modulator of the ErbB2 oncogenic receptor

International Journal of Molecular Sciences

Volumn 18, Issue 11, 2017, Pages

  Duarte, Henrique O ^a,b   Balmaña, Meritxell ^a,b   Mereiter, Stefan ^a,b   Osório, Hugo ^a,b,c   Gomes, Joana ^a,b   Reis, Celso A ^a,b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

Author keywords

CA 19.9; Gastric cancer (GC); Glycosylation; Human epidermal growth factor receptor 2 (ErbB2); Sialyl Lewis a (SLea)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOSYLTRANSFERASE; SIALYL LEWIS X ANTIGEN; TUMOR ANTIGEN; TUNICAMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; POLYSACCHARIDE; TUMOR MARKER;

ARTICLE; BIOINFORMATICS; CARCINOGENESIS; CONTROLLED STUDY; DEGLYCOSYLATION; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING; BIOLOGY; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIGENE FAMILY; PROCEDURES; STOMACH TUMOR; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; GLYCOSYLTRANSFERASES; HUMANS; MULTIGENE FAMILY; POLYSACCHARIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMACH NEOPLASMS;

EID: 85032689258     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18112262     Document Type: Article

References (64)

1. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.; Bray, F. Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries in 2012. Eur. J. Cancer 2013, 49, 1374–1403. [CrossRef] [PubMed]
2. Waddell, T.; Verheij, M.; Allum, W.; Cunningham, D.; Cervantes, A.; Arnold, D. Gastric Cancer: Esmo–Esso–Estro Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2013, 24 (Suppl. 6), vi57–vi63. [CrossRef] [PubMed]
3. Yan, M.; Schwaederle, M.; Arguello, D.; Millis, S.Z.; Gatalica, Z.; Kurzrock, R. HER2 Expression Status in Diverse Cancers: Review of Results from 37,992 Patients. Cancer Metastasis Rev. 2015, 34, 157–164. [CrossRef] [PubMed]
4. Gravalos, C.; Jimeno, A. HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Ann. Oncol. 2008, 19, 1523–1529. [CrossRef] [PubMed]
5. Burgess, A.W.; Cho, H.S.; Eigenbrot, C.; Ferguson, K.M.; Garrett, T.P.; Leahy, D.J.; Lemmon, M.A.; Sliwkowski, M.X.; Ward, C.W.; Yokoyama, S. An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. Mol. Cell 2003, 12, 541–552. [CrossRef]
6. Hynes, N.E.; Stern, D.F. The Biology of Erbb-2/Nue/Her-2 and Its Role in Cancer. Biochim. Biophys. Acta 1994, 1198, 165–184. [CrossRef]
7. Hynes, N.E.; Lane, H.A. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors. Nat. Rev. Cancer 2005, 5, 341–354. [CrossRef] [PubMed]
8. Bang, Y.J.; van Cutsem, E.; Feyereislova, A.; Chung, H.C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T. Trastuzumab in Combination with Chemotherapy Versus Chemotherapy Alone for Treatment of Her2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (Toga): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet 2010, 376, 687–697. [CrossRef]
9. Roukos, D.H. Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance. Ann. Surg. Oncol. 2010, 17, 14–17. [CrossRef] [PubMed]
10. Shah, M.A.; Xu, R.H.; Bang, Y.J.; Hoff, P.M.; Liu, T.; Herráez-Baranda, L.A.; Xia, F.; Garg, A.; Shing, M.; Tabernero, J. Heloise: Phase Iiib Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined with Chemotherapy as First-Line Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. J. Clin. Oncol. 2017, 35, 2558–2567. [PubMed]
11. Varki, A.; Stanley, P.; Schachter, H.; Taniguchi, N. Essentials of Glycobiology; Cold Spring Cold Spring Harbor Laboratory Press: Harbor, NY, USA, 2009.
12. Pinho, S.S.; Reis, C.A. Glycosylation in Cancer: Mechanisms and Clinical Implications. Nat. Rev. Cancer 2015, 15, 540–555. [CrossRef] [PubMed]
13. Pinho, S.S.; Carvalho, S.; Marcos-Pinto, R.; Magalhães, A.; Oliveira, C.; Gu, J.; Dinis-Ribeiro, M.; Carneiro, F.; Seruca, R.; Reis, C.A. Gastric Cancer: Adding Glycosylation to the Equation. Trends Mol. Med. 2013, 19, 664–676. [CrossRef] [PubMed]
14. Mereiter, S.; Balmaña, M.; Gomes, J.; Magalhães, A.; Reis, C.A. Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer. Front. Oncol. 2016, 6, 55. [CrossRef] [PubMed]
15. Contessa, J.N.; Bhojani, M.S.; Freeze, H.H.; Rehemtulla, A.; Lawrence, T.S. Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells. Cancer Res. 2008, 68, 3803–3809. [CrossRef] [PubMed]
16. Liu, Y.C.; Yen, H.Y.; Chen, C.Y.; Chen, C.H.; Cheng, P.F.; Juan, Y.H.; Chen, C.H.; Khoo, K.H.; Yu, C.J.; Yang, P.C.; et al. Sialylation and Fucosylation of Epidermal Growth Factor Receptor Suppress Its Dimerization and Activation in Lung Cancer Cells. Proc. Natl. Acad. Sci. USA 2011, 108, 11332–11337. [CrossRef] [PubMed]
17. Matsumoto, K.; Yokote, H.; Arao, T.; Maegawa, M.; Tanaka, K.; Fujita, Y.; Shimizu, C.; Hanafusa, T.; Fujiwara, Y.; Nishio, K. N-Glycan Fucosylation of Epidermal Growth Factor Receptor Modulates Receptor Activity and Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Cancer Sci. 2008, 99, 1611–1617. [CrossRef] [PubMed]
18. Wang, X.; Gu, J.; Ihara, H.; Miyoshi, E.; Honke, K.; Taniguchi, N. Core Fucosylation Regulates Epidermal Growth Factor Receptor-Mediated Intracellular Signaling. J. Biol. Chem. 2006, 281, 2572–2577. [CrossRef] [PubMed]
19. Lopez-Sambrooks, C.; Shrimal, S.; Khodier, C.; Flaherty, D.P.; Rinis, N.; Charest, J.C.; Gao, N.; Zhao, P.; Wells, L.; Lewis, T.A.; et al. Oligosaccharyltransferase Inhibition Induces Senescence in Rtk-Driven Tumor Cells. Nat. Chem. Biol. 2016, 12, 1023–1030. [CrossRef] [PubMed]
20. Mereiter, S.; Magalhães, A.; Adamczyk, B.; Jin, C.; Almeida, A.; Drici, L.; Ibáñez-Vea, M.; Gomes, C.; Ferreira, J.A.; Afonso, L.P.; et al. Glycomic Analysis of Gastric Carcinoma Cells Discloses Glycans as Modulators of Ron Receptor Tyrosine Kinase Activation in Cancer. Biochim. Biophys. Acta 2016, 1860, 1795–1808. [CrossRef] [PubMed]
21. Frei, A.P.; Jeon, O.Y.; Kilcher, S.; Moest, H.; Henning, L.M.; Jost, C.; Plückthun, A.; Mercer, J.; Aebersold, R.; Carreira, E.M.; et al. Direct Identification of Ligand-Receptor Interactions on Living Cells and Tissues. Nat. Biotechnol. 2012, 30, 997–1001. [CrossRef] [PubMed]
22. Watanabe, M.; Terasawa, K.; Kaneshiro, K.; Uchimura, H.; Yamamoto, R.; Fukuyama, Y.; Shimizu, K.; Sato, T.A.; Tanaka, K. Improvement of Mass Spectrometry Analysis of Glycoproteins by Maldi-Ms Using 3-Aminoquinoline/A-Cyano-4-Hydroxycinnamic Acid. Anal. Bioanal. Chem. 2013, 405, 4289–4293. [CrossRef] [PubMed]
23. Carvalho, A.S.; Harduin-Lepers, A.; Magalhaes, A.; Machado, E.; Mendes, N.; Costa, L.T.; Matthiesen, R.; Almeida, R.; Costa, J.; Reis, C.A. Differential Expression of A-2, 3-Sialyltransferases and A-1, 3/4-Fucosyltransferases Regulates the Levels of Sialyl Lewis a and Sialyl Lewis X in Gastrointestinal Carcinoma Cells. Int. J. Biochem. Cell Biol. 2010, 42, 80–89. [PubMed]
24. Sterner, E.; Flanagan, N.; Gildersleeve, J.C. Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database. ACS Chem. Biol. 2016, 11, 1773–1783. [CrossRef] [PubMed]
25. Kudo, T.; Narimatsu, H. Fucosyltransferase 3. Gdp-Fucose Lactosamine A1, 3/4-Fucosyltransferase. Lea and Leb Histo-Blood Groups (Fut3, Lewis Enzyme). In Handbook of Glycosyltransferases and Related Genes; Springer Science & Business Media: Berlin, Germany, 2014; pp. 531–539.
26. Ohtsubo, K.; Marth, J.D. Glycosylation in Cellular Mechanisms of Health and Disease. Cell 2006, 126, 855–867. [CrossRef] [PubMed]
27. Klinger, M.; Farhan, H.; Just, H.; Drobny, H.; Himmler, G.; Loibner, H.; Mudde, G.C.; Freissmuth, M.; Sexl, V. Antibodies Directed against Lewis-Y Antigen Inhibit Signaling of Lewis-Y Modified Erbb Receptors. Cancer Res. 2004, 64, 1087–1093. [CrossRef] [PubMed]
28. Tanner, M.; Hollmén, M.; Junttila, T.T.; Kapanen, A.I.; Tommola, S.; Soini, Y.; Helin, H.; Salo, J.; Joensuu, H.; Sihvo, E.; et al. Amplification of HER-2 in Gastric Carcinoma: Association with Topoisomerase IIα Gene Amplification, Intestinal Type, Poor Prognosis and Sensitivity to Trastuzumab. Ann. Oncol. 2005, 16, 273–278. [CrossRef] [PubMed]
29. Brennan, P.J.; Kumagai, T.; Berezov, A.; Murali, R.; Greene, M.I. HER2/Neu: Mechanisms of Dimerization/Oligomerization. Oncogene 2000, 19, 6093–6101. [CrossRef] [PubMed]
30. Graus-Porta, D.; Beerli, R.R.; Hynes, N.E. Single-Chain Antibody-Mediated Intracellular Retention of Erbb-2 Impairs Neu Differentiation Factor and Epidermal Growth Factor Signaling. Mol. Cell. Biol. 1995, 15, 1182–1191. [CrossRef] [PubMed]
31. Tzahar, E.; Waterman, H.; Chen, X.; Levkowitz, G.; Karunagaran, D.; Lavi, S.; Ratzkin, B.J.; Yarden, Y. A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor. Mol. Cell. Biol. 1996, 16, 5276–5287. [CrossRef] [PubMed]
32. Tsuda, T.; Ikeda, Y.; Taniguchi, N. The Asn-420-Linked Sugar Chain in Human Epidermal Growth Factor Receptor Suppresses Ligand-Independent Spontaneous Oligomerization Possible Role of a Specific Sugar Chain in Controllable Receptor Activation. J. Biol. Chem. 2000, 275, 21988–21994. [CrossRef] [PubMed]
33. Fernandes, H.; Cohen, S.; Bishayee, S. Glycosylation-Induced Conformational Modification Positively Regulates Receptor-Receptor Association a Study with an Aberrant Epidermal Growth Factor Receptor (Egfrviii/∆egfr) Expressed in Cancer Cells. J. Biol. Chem. 2001, 276, 5375–5383. [CrossRef] [PubMed]
34. Yokoe, S.; Takahashi, M.; Asahi, M.; Lee, S.H.; Li, W.; Osumi, D.; Miyoshi, E.; Taniguchi, N. The Asn418-Linked N-Glycan of Erbb3 Plays a Crucial Role in Preventing Spontaneous Heterodimerization and Tumor Promotion. Cancer Res. 2007, 67, 1935–1942. [CrossRef] [PubMed]
35. Takahashi, M.; Yokoe, S.; Asahi, M.; Lee, S.H.; Li, W.; Osumi, D.; Miyoshi, E.; Taniguchi, N. N-Glycan of Erbb Family Plays a Crucial Role in Dimer Formation and Tumor Promotion. Biochim. Biophys. Acta 2008, 1780, 520–524. [CrossRef] [PubMed]
36. Ashkani, J.; Naidoo, K.J. Glycosyltransferase Gene Expression Profiles Classify Cancer Types and Propose Prognostic Subtypes. Sci. Rep. 2016, 6. [CrossRef] [PubMed]
37. Magalhães, A.; Rossez, Y.; Robbe-Masselot, C.; Maes, E.; Gomes, J.; Shevtsova, A.; Bugaytsova, J.; Borén, T.; Reis, C.A. Muc5ac Gastric Mucin Glycosylation Is Shaped by Fut2 Activity and Functionally Impacts Helicobacter Pylori Binding. Sci. Rep. 2016, 6, 25575. [CrossRef] [PubMed]
38. Trinchera, M.; Aronica, A.; Dall’Olio, F. Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis X in Gastrointestinal Cancers. Biology 2017, 6. [CrossRef] [PubMed]
39. Chen, L.; Zhang, W.; Fregien, N.; Pierce, M. The Her-2/Neu Oncogene Stimulates the Transcription of N-Acetylglucosaminyltransferase V and Expression of Its Cell Surface Oligosaccharide Products. Oncogene 1998, 17, 2087–2093. [CrossRef] [PubMed]
40. Buckhaults, P.; Chen, L.; Fregien, N.; Pierce, M. Transcriptional Regulation of N-acetylglucosaminyltransferase V by the Srconcogene. J. Biol. Chem. 1997, 272, 19575–19581. [CrossRef] [PubMed]
41. Guo, H.B.; Johnson, H.; Randolph, M.; Nagy, T.; Blalock, R.; Pierce, M. Specific Posttranslational Modification Regulates Early Events in Mammary Carcinoma Formation. Proc. Natl Acad. Sci. USA 2010, 107, 21116–21121. [CrossRef] [PubMed]
42. Hadari, Y.R.; Doody, J.F.; Wang, Y.; Patel, S.N.; Apblett, R.L.; Loizos, N.; Pereira, D.S.; Witte, L.; Bohlen, P.; Hicklin, D.J. The Igg1 Monoclonal Antibody Cetuximab Induces Degradation of the Epidermal Growth Factor Receptor. In Proceedings of the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 22–24 January 2004.
43. Anderson, W.F.; Camargo, M.C.; Fraumeni, J.F., Jr.; Correa, P.; Rosenberg, P.S.; Rabkin, C.S. Age-Specific Trends in Incidence of Noncardia Gastric Cancer in US Adults. JAMA 2010, 303, 1723–1728. [CrossRef] [PubMed]
44. Weston, B.W.; Hiller, K.M.; Mayben, J.P.; Manousos, G.A.; Bendt, K.M.; Liu, R.; Cusack, J.C., Jr. Expression of Human A (1, 3) Fucosyltransferase Antisense Sequences Inhibits Selectin-Mediated Adhesion and Liver Metastasis of Colon Carcinoma Cells. Cancer Res. 1999, 59, 2127–2135. [PubMed]
45. Opolski, A.; Laskowska, A.; Madej, J.; Wietrzyk, J.; Kłopocki, A.; Radzikowski, C.; Ugorski, M. Metastatic Potential of Human Cx-1 Colon Adenocarcinoma Cells is Dependent on the Expression of Sialosyl Le a Antigen. Clin. Exp. Metastasis 1998, 16, 673–681. [CrossRef] [PubMed]
46. Mahdavi, J.; Sondén, B.; Hurtig, M.; Olfat, F.O.; Forsberg, L.; Roche, N.; Angstrom, J.; Larsson, T.; Teneberg, S.; Karlsson, K.A.; et al. Helicobacter Pylori Saba Adhesin in Persistent Infection and Chronic Inflammation. Science 2002, 297, 573–578. [CrossRef] [PubMed]
47. Hiller, K.M.; Mayben, J.P.; Bendt, K.M.; Manousos, G.A.; Senger, K.; Cameron, H.S.; Weston, B.W. Transfection of A (1, 3) Fucosyltransferase Antisense Sequences Impairs the Proliferative and Tumorigenic Ability of Human Colon Carcinoma Cells. Mol. Carcinog. 2000, 27, 280–288. [CrossRef]
48. Terraneo, L.; Avagliano, L.; Caretti, A.; Bianciardi, P.; Tosi, D.; Bulfamante, G.P.; Samaja, M.; Trinchera, M. Expression of Carbohydrate-Antigen Sialyl-Lewis a on Colon Cancer Cells Promotes Xenograft Growth and Angiogenesis in Nude Mice. Int. J. Biochem. Cell Biol. 2013, 45, 2796–2800. [CrossRef] [PubMed]
49. Steinberg, W. The Clinical Utility of the Ca 19–9 Tumor-Associated Antigen. Am. J. Gastroenterol. 1990, 85, 350–355. [PubMed]
50. Holdenrieder, S.; Pagliaro, L.; Morgenstern, D.; Dayyani, F. Clinically Meaningful Use of Blood Tumor Markers in Oncology. BioMed Res. Int. 2016, 2016, 9795269. [CrossRef] [PubMed]
51. Reis, C.A.; Osorio, H.; Silva, L.; Gomes, C.; David, L. Alterations in Glycosylation as Biomarkers for Cancer Detection. J. Clin. Pathol. 2010, 63, 322–329. [CrossRef] [PubMed]
52. Perng, C.L.; Lin, H.J.; Lee, S.D. Serum C-Erbb-2 Oncoprotein in the Diagnosis of Gastric Cancer in Comparison with Ca 19–9, Cea, Tpa, Ca 125 and Afp. Zhonghua yi xue za zhi 1994, 54, 82–86. [PubMed]
53. Molina, R.; Jo, J.; Filella, X.; Bruix, J.; Castells, A.; Hague, M.; Ballesta, A.M. Serum Levels of C-Erbb-2 (Her-2/Neu) in Patients with Malignant and Non-Malignant Diseases. Tumor Biol. 1997, 18, 188–196. [CrossRef]
54. Kono, K.; Naganuma, H.; Sekikawa, T.; Amemiya, H.; Takahashi, A.; Iizuka, H.; Matsumoto, Y. Serum Level of Her-2/Neu in Patients with Gastric Cancer: Correlation with Her-2/Neu Overexpression in Gastric Carcinoma Tissue. Tumor Biol. 2000, 21, 139–144. [CrossRef]
55. Wong, H.; Yau, T. Molecular Targeted Therapies in Advanced Gastric Cancer: Does Tumor Histology Matter? Therap. Adv. Gastroenterol. 2013, 6, 15–31. [CrossRef] [PubMed]
56. Colcher, D.; Hand, P.H.; Nuti, M.; Schlom, J. A Spectrum of Monoclonal Antibodies Reactive with Human Mammary Tumor Cells. Proc. Natl. Acad. Sci. USA 1981, 78, 3199–3203. [CrossRef] [PubMed]
57. Young, W.W., Jr.; Portoukalian, J.; Hakomori, S. Two Monoclonal Anticarbohydrate Antibodies Directed to Glycosphingolipids with a Lacto-N-Glycosyl Type II Chain. J. Biol. Chem. 1981, 256, 10967–10972. [PubMed]
58. Fukushi, Y.; Hakomori, S.; Nudelman, E.; Cochran, N. Novel Fucolipids Accumulating in Human Adenocarcinoma. II. Selective Isolation of Hybridoma Antibodies That Differentially Recognize Mono-, Di-, and Trifucosylated Type 2 Chain. J. Biol. Chem. 1984, 259, 4681–4685. [PubMed]
59. Abe, K.; McKibbin, J.M.; Hakomori, S. The Monoclonal Antibody Directed to Difucosylated Type 2 Chain (Fuc Alpha 1 Leads to 2gal Beta 1 Leads to 4 [Fuc Alpha 1 Leads to 3] Glcnac; Y Determinant). J. Biol. Chem. 1983, 258, 11793–11797. [PubMed]
60. Livak, K.J.; Schmittgen, T.D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative Pcr and the 2-∆δct Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
61. Ferreirinha, P.; Correia, A.; Teixeira-Coelho, M.; Osório, H.; Teixeira, L.; Rocha, A.; Vilanova, M. Mucosal Immunization Confers Long-Term Protection against Intragastrically Established Neospora Caninum Infection. Vaccine 2016, 34, 6250–6258. [CrossRef] [PubMed]
62. Rhodes, D.R.; Yu, J.; Shanker, K.; Deshpande, N.; Varambally, R.; Ghosh, D.; Barrette, T.; Pandey, A.; Chinnaiyan, A.M. Oncomine: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia 2004, 6, 1–6. [CrossRef]
63. Barretina, J.; Caponigro, G.; Stransky, N.; Venkatesan, K.; Margolin, A.A.; Kim, S.; Wilson, C.J.; Lehár, J.; Kryukov, G.V.; Sonkin, D.; et al. The Cancer Cell Line Encyclopedia Enables Predictive Modelling of Anticancer Drug Sensitivity. Nature 2012, 483, 603–607. [CrossRef] [PubMed]
64. Ooi, W.F.; Xing, M.; Xu, C.; Yao, X.; Ramlee, M.K.; Lim, M.C.; Cao, F.; Lim, K.; Babu, D.; Poon, L.F. Epigenomic Profiling of Primary Gastric Adenocarcinoma Reveals Super-Enhancer Heterogeneity. Nat. Commun. 2016, 7, 12983. [CrossRef] [PubMed]